US Patent

US9585892 — Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-Nâ²-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions thereof, and uses therewith

Method of Use · Assigned to Ambit Bioscience Corp · Expires 2027-03-16 · 1y remaining

Vulnerability score 88/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects solid forms of the drug quizartinib dihydrochloride and methods of using them to treat various diseases and/or disorders.

USPTO Abstract

Solid forms comprising N-(5-tert-butyl-isoxazol-3-yl)-Nâ²-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea, compositions comprising the solid forms, methods of making the solid forms and methods of their use for the treatment of various diseases and/or disorders are disclosed.

Drugs covered by this patent

quizartinib-dihydrochloride (QUIZARTINIB DIHYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3661`	—	quizartinib-dihydrochloride
`U-3661`	—	quizartinib-dihydrochloride

Patent Metadata

Patent number: US9585892
Jurisdiction: US
Classification: Method of Use
Expires: 2027-03-16
Drug substance claim: No
Drug product claim: No
Assignee: Ambit Bioscience Corp
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.